Endo Gains Phase II Oral Mucositis Agent With RxKinetix Acquisition
This article was originally published in The Pink Sheet Daily
Agreement is in line with Endo’s strategy of expanding into therapeutic areas complementary to pain.
You may also be interested in...
Scripts for Endo's oral oxymorphone reached 1,137 the week of Sept. 29, according to IMS weekly trend data.
The firm will add 220 sales reps to support the July launch of the extended-release and immediate-release opioid analgesics.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.